Drug developer Scholar Rock's Q3 net loss widens
Overview
Scholar Rock Q3 net loss widens to $102.2 mln, no revenue recorded
Operating expenses increased due to apitegromab launch readiness
Company expects cash reserves to fund operations into 2027
Outlook
Scholar Rock anticipates U.S. launch of apitegromab in 2026
Company reserves commercial capacity for apitegromab starting Q1 2026
Scholar Rock expects to start SRK-439 dosing in Q4 2025
Result Drivers
Research and development expense was $50.5 million, including $5.5 million in stock-based compensation, for the quarter ended September 30, 2025, compared to $48.7 million, including $4.4 million in stock-based compensation, for the quarter ended September 30, 2024
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 EPS | -$0.90 | ||
Q3 Net Income | -$102.22 mln | ||
Q3 Income from Operations | -$103.55 mln | ||
Q3 Operating Expenses | $103.55 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Scholar Rock Holding Corp is $45.00, about 33.2% above its November 13 closing price of $30.07
Press Release:
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
